160 related articles for article (PubMed ID: 35869020)
1. Up-front Therapy With CHOP Plus Etoposide in Brazilian nodal PTCL Patients: Increased Toxicity and No Survival Benefit Compared to CHOP Regimen-Results of a Real-Life Study From a Middle-Income Country.
Lage LAPC; Brito CV; Barreto GC; Culler HF; Reichert CO; Levy D; Costa RO; Zerbini MCN; Rocha V; Pereira J
Clin Lymphoma Myeloma Leuk; 2022 Nov; 22(11):812-824. PubMed ID: 35869020
[TBL] [Abstract][Full Text] [Related]
2. Practicability and acute haematological toxicity of 2- and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin's lymphoma: results from the NHL-B trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).
Wunderlich A; Kloess M; Reiser M; Rudolph C; Truemper L; Bittner S; Schmalenberg H; Schmits R; Pfreundschuh M; Loeffler M;
Ann Oncol; 2003 Jun; 14(6):881-93. PubMed ID: 12796026
[TBL] [Abstract][Full Text] [Related]
3. Randomised comparison of CHOEP versus alternating hCHOP/IVEP for high-grade non-Hodgkin's lymphomas: treatment results and prognostic factor analysis in a multi-centre trial.
Köppler H; Pflüger KH; Eschenbach I; Pfab R; Birkmann J; Zeller W; Holle R; Steinhauer UE; Gropp C; Oehl S
Ann Oncol; 1994 Jan; 5(1):49-55. PubMed ID: 8172793
[TBL] [Abstract][Full Text] [Related]
4. Chemotherapy with cyclophosphamide, doxorubicin, etoposide, vincristine and prednisone (CHOEP) is not effective in patients with enteropathy-type intestinal T-cell lymphoma.
Wöhrer S; Chott A; Drach J; Püspök A; Hejna M; Hoffmann M; Raderer M
Ann Oncol; 2004 Nov; 15(11):1680-3. PubMed ID: 15520071
[TBL] [Abstract][Full Text] [Related]
5. Impact of etoposide and ASCT on survival among patients aged <65 years with stage II to IV PTCL: a population-based cohort study.
Brink M; Meeuwes FO; van der Poel MWM; Kersten MJ; Wondergem M; Mutsaers PGNJ; Böhmer LH; Woei-A-Jin FJSH; Visser O; Oostvogels R; Jansen PM; Plattel W; Huls GA; Vermaat JSP; Nijland M
Blood; 2022 Sep; 140(9):1009-1019. PubMed ID: 35544601
[TBL] [Abstract][Full Text] [Related]
6. Long-time follow-up of patients with untreated peripheral T cell lymphoma following chidamide combined with cyclophosphamide, epirubicin, vindesine, prednisone, and etoposide therapy: a single-center propensity score-matching study.
Wei C; Zhao D; Zhang Y; Wang W; Zhou D; Zhang W
Clin Transl Oncol; 2023 Aug; 25(8):2514-2522. PubMed ID: 37020164
[TBL] [Abstract][Full Text] [Related]
7. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.
Chiappella A; Martelli M; Angelucci E; Brusamolino E; Evangelista A; Carella AM; Stelitano C; Rossi G; Balzarotti M; Merli F; Gaidano G; Pavone V; Rigacci L; Zaja F; D'Arco A; Cascavilla N; Russo E; Castellino A; Gotti M; Congiu AG; Cabras MG; Tucci A; Agostinelli C; Ciccone G; Pileri SA; Vitolo U
Lancet Oncol; 2017 Aug; 18(8):1076-1088. PubMed ID: 28668386
[TBL] [Abstract][Full Text] [Related]
8. A retrospective study of the CHOP, CHOPE, and CHOPE/G regimens as the first-line treatment of peripheral T-cell lymphomas.
Liu X; Yang M; Wu M; Zheng W; Xie Y; Zhu J; Song Y; Liu W
Cancer Chemother Pharmacol; 2019 Mar; 83(3):443-449. PubMed ID: 30511217
[TBL] [Abstract][Full Text] [Related]
9. Peripheral T-cell lymphoma: the role of hematopoietic stem cell transplantation.
Gkotzamanidou M; Papadimitriou CA
Crit Rev Oncol Hematol; 2014 Feb; 89(2):248-61. PubMed ID: 24075060
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of a dose-intensified CHOP (Double-CHOP) regimen for peripheral T-cell lymphomas.
Iriyama N; Takahashi H; Hatta Y; Miura K; Kobayashi Y; Kurita D; Hirabayashi Y; Hojo A; Kodaira H; Yagi M; Kiso S; Uchino Y; Nakagawa M; Kusuda M; Kobayashi S; Horikoshi A; Kura Y; Yamazaki T; Sawada U; Takeuchi J
Oncol Rep; 2013 Feb; 29(2):805-11. PubMed ID: 23166041
[TBL] [Abstract][Full Text] [Related]
11. First-line therapy for T cell lymphomas: a retrospective population-based analysis of 906 T cell lymphoma patients.
Janikova A; Chloupkova R; Campr V; Klener P; Hamouzova J; Belada D; Prochazka V; Pytlik R; Pirnos J; Duras J; Mocikova H; Bortlicek Z; Kopalova N; Mayer J; Trneny M
Ann Hematol; 2019 Aug; 98(8):1961-1972. PubMed ID: 31065733
[TBL] [Abstract][Full Text] [Related]
12. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01.
d'Amore F; Relander T; Lauritzsen GF; Jantunen E; Hagberg H; Anderson H; Holte H; Österborg A; Merup M; Brown P; Kuittinen O; Erlanson M; Østenstad B; Fagerli UM; Gadeberg OV; Sundström C; Delabie J; Ralfkiaer E; Vornanen M; Toldbod HE
J Clin Oncol; 2012 Sep; 30(25):3093-9. PubMed ID: 22851556
[TBL] [Abstract][Full Text] [Related]
13. A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T- cell consortium trial.
Advani RH; Ansell SM; Lechowicz MJ; Beaven AW; Loberiza F; Carson KR; Evens AM; Foss F; Horwitz S; Pro B; Pinter-Brown LC; Smith SM; Shustov AR; Savage KJ; Vose JM
Br J Haematol; 2016 Feb; 172(4):535-44. PubMed ID: 26627450
[TBL] [Abstract][Full Text] [Related]
14. Comparison of gemcitabin, cisplatin, and dexamethasone (GDP), CHOP, and CHOPE in the first-line treatment of peripheral T-cell lymphomas.
Jia B; Hu S; Yang J; Zhou S; Liu P; Qin Y; Gui L; Yang S; Lin H; Zhang C; Xing P; Wang L; Dong M; Zhou L; Sun Y; He X; Shi Y
Hematology; 2016 Oct; 21(9):536-41. PubMed ID: 27077778
[TBL] [Abstract][Full Text] [Related]
15. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL.
Pfreundschuh M; Trümper L; Kloess M; Schmits R; Feller AC; Rudolph C; Reiser M; Hossfeld DK; Metzner B; Hasenclever D; Schmitz N; Glass B; Rübe C; Loeffler M;
Blood; 2004 Aug; 104(3):626-33. PubMed ID: 14982884
[TBL] [Abstract][Full Text] [Related]
16. Rituximab plus high-dose chemotherapy (MegaCHOEP) or conventional chemotherapy (CHOEP-14) in young, high-risk patients with aggressive B-cell lymphoma: 10-year follow-up of a randomised, open-label, phase 3 trial.
Frontzek F; Ziepert M; Nickelsen M; Altmann B; Glass B; Haenel M; Truemper L; Held G; Bentz M; Borchmann P; Dreyling M; Viardot A; Kroschinsky FP; Metzner B; Staiger AM; Horn H; Ott G; Rosenwald A; Loeffler M; Lenz G; Schmitz N
Lancet Haematol; 2021 Apr; 8(4):e267-e277. PubMed ID: 33667420
[TBL] [Abstract][Full Text] [Related]
17. High-dose extended-field radiotherapy plus chemotherapy improved survival in extranodal NK/T-cell lymphoma in a real-life setting: results from the multicenter T-Cell Brazil Project.
de Pádua Covas Lage LA; Machado PPF; Reichert CO; Miranda E; Culler HF; da Siqueira SAC; de Oliveira Costa R; Miyashiro DR; Sanches JA; Rocha V; Chiattone CS; Pereira J
Sci Rep; 2022 Nov; 12(1):20557. PubMed ID: 36446856
[TBL] [Abstract][Full Text] [Related]
18. Real-world treatment patterns, healthcare resource utilization and costs among patients with peripheral T-cell lymphoma.
Dharmani C; Unni S; Pham N; Shaikh NF; Xiong Y; Vashi R; Fofah O; Strubing A; Salas M; Tu N; Wooddell M; Zhou X; Near A
Future Oncol; 2024 May; 20(15):1013-1030. PubMed ID: 37814886
[TBL] [Abstract][Full Text] [Related]
19. Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma.
Mercadal S; Briones J; Xicoy B; Pedro C; Escoda L; Estany C; Camós M; Colomo L; Espinosa I; Martínez S; Ribera JM; Martino R; Gutiérrez-García G; Montserrat E; López-Guillermo A;
Ann Oncol; 2008 May; 19(5):958-63. PubMed ID: 18303032
[TBL] [Abstract][Full Text] [Related]
20. Romidepsin Plus CHOP Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Results of the Ro-CHOP Phase III Study (Conducted by LYSA).
Bachy E; Camus V; Thieblemont C; Sibon D; Casasnovas RO; Ysebaert L; Damaj G; Guidez S; Pica GM; Kim WS; Lim ST; André M; García-Sancho AM; Penarrubia MJ; Staber PB; Trotman J; Hüttmann A; Stefoni V; Re A; Gaulard P; Delfau-Larue MH; de Leval L; Meignan M; Li J; Morschhauser F; Delarue R
J Clin Oncol; 2022 Jan; 40(3):242-251. PubMed ID: 34843406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
